In the Claims:

Please amend the following claims:

10. (Amended) A method for treating a human patient for coronary artery disease comprising, administering a [safe and] therapeutically effective amount of a recombinant FGF-2 or an angiogenically active fragment or mutein thereof to one or more coronary vessels or to a peripheral vein in a human patient in need of treatment for said coronary artery disease, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight.

~~19~~ 10. (Amended) The method of claim ~~18~~ 9, wherein said single unit dose produces a therapeutic benefit against coronary artery disease in said human patient that lasts at least four months.

~~20~~ 11. (Amended) The method of claim ~~19~~ 10, wherein said [single unit dose produces a] therapeutic benefit in said human patient [that] lasts 6 months.

~~21~~ 12. (Amended) The method of claim ~~20~~ 11, wherein said [single unit dose produces a] therapeutic benefit is of such magnitude and duration in said human patient such that administration of a second unit dose is not required for about 6 months.

Please add the following claims:

--35. A method for providing a human patient with relief from symptoms of angina comprising administering a single unit dose of a recombinant FGF-2 or an angiogenically active fragment or mutein thereof to one or more coronary